Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI – Get Free Report) has received an average recommendation of “Moderate Buy” from the nine brokerages that are covering the company, MarketBeat Ratings reports. Three analysts have rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $10.78.
Several research firms recently issued reports on MRVI. Morgan Stanley lowered Maravai LifeSciences from an “overweight” rating to an “equal weight” rating and decreased their target price for the stock from $11.00 to $10.00 in a research note on Tuesday, August 13th. The Goldman Sachs Group increased their price target on shares of Maravai LifeSciences from $7.00 to $8.00 and gave the stock a “neutral” rating in a research report on Thursday, August 8th. Wells Fargo & Company initiated coverage on shares of Maravai LifeSciences in a report on Tuesday, August 27th. They issued an “overweight” rating and a $10.00 price objective for the company. Royal Bank of Canada reaffirmed an “outperform” rating and set a $15.00 target price on shares of Maravai LifeSciences in a research note on Friday, August 16th. Finally, UBS Group raised their price target on shares of Maravai LifeSciences from $8.50 to $11.00 and gave the company a “neutral” rating in a research report on Thursday, August 8th.
Read Our Latest Stock Analysis on Maravai LifeSciences
Institutional Inflows and Outflows
Maravai LifeSciences Stock Performance
Shares of MRVI stock opened at $9.05 on Friday. Maravai LifeSciences has a one year low of $4.52 and a one year high of $11.56. The company has a debt-to-equity ratio of 0.71, a quick ratio of 9.28 and a current ratio of 10.00. The firm’s 50 day moving average price is $8.62 and its 200-day moving average price is $8.46. The firm has a market cap of $2.28 billion, a P/E ratio of -9.14 and a beta of 0.01.
Maravai LifeSciences (NASDAQ:MRVI – Get Free Report) last released its quarterly earnings results on Wednesday, August 7th. The company reported ($0.08) EPS for the quarter. Maravai LifeSciences had a negative return on equity of 4.78% and a negative net margin of 47.41%. The firm had revenue of $73.40 million for the quarter, compared to analyst estimates of $71.64 million. During the same quarter last year, the company earned ($0.06) earnings per share. The firm’s revenue for the quarter was up 6.5% on a year-over-year basis. As a group, equities research analysts predict that Maravai LifeSciences will post -0.17 EPS for the current year.
About Maravai LifeSciences
Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.
See Also
- Five stocks we like better than Maravai LifeSciences
- EV Stocks and How to Profit from Them
- Is Merck Stock Undervalued After Its Colossal Earnings Growth?
- Stock Analyst Ratings and Canadian Analyst Ratings
- Top 5 ETFs for Every Investor: From Semiconductors to Defense
- Why Are These Companies Considered Blue Chips?
- Blade Air Mobility: This Under-the-Radar Stock Could Double Soon
Receive News & Ratings for Maravai LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maravai LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.